AbbVie shared on LinkedIn:
“For patients with difficult-to-treat cancers, significant unmet needs remain despite advances in treatment.
We are pleased to share that the U.S. FDA has granted two Breakthrough Therapy Designations for our investigational treatment in colorectal cancer (CRC) and non-small cell lung cancer (NSCLC).
This important milestone underscores our commitment to scientific innovation across multiple tumor types.”
Read more here.
Proceed to the video attached to the post.
Michael Burns, Clinical Development Senior Medical Director at Pfizer, added:
“Great to see this milestone for Temab-A and the patients it may ultimately help. I’m proud to have been part of the team that helped advance this program in its early development, and it’s exciting to see this announcement. Congratulations to the AbbVie team!”
Read more articles about AbbVie on OncoDaily.